- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 30, 2021
Distillery Therapeutics
Inhibiting RPS6KA6 with floxacin antibiotics for bladder, lung cancers
DISEASE CATEGORY: Cancer
INDICATION: Bladder cancer; lung cancer Derivatives of the antibiotics moxifloxacin and trovafloxacin and other inhibitors of RPS6KA6 could treat bladder and lung
INDICATION: Bladder cancer; lung cancer Derivatives of the antibiotics moxifloxacin and trovafloxacin and other inhibitors of RPS6KA6 could treat bladder and lung
BioCentury | Feb 19, 2021
Translation in Brief
mAb reduces amyloid plaques without hemorrhage; plus Dyno and Ally’s AAV technologies and more
BioCentury’s roundup of translational news
BioCentury | May 21, 2020
Finance
HotSpot heads for clinic with $65M series B round to develop allosteric modulators
With strategics, one crossover on board, HotSpot is likely to raise mezzanine round before exploring IPO
BioCentury | Nov 21, 2019
Financial News
Nov. 20 Financial Quick Takes: Diagnostics play Lucence raises series A; plus Novo-Broad, PMV, Phoenix, Winterlight and BMS-Celgene
BioCentury | Feb 22, 2019
Targets & Mechanisms
Expansion into TNBC
How RNA-binding small molecules could sensitize TNBC to targeted therapies
BioCentury | Feb 8, 2019
Product R&D
Reducing R(i)SK in TNBC
Phoenix aims to make RSK2 the first positive marker to stratify TNBC patients
BioCentury | Jul 20, 2018
Financial News
Hotspot debuts with $45M to find, drug natural allosteric sites
BioCentury | Jul 17, 2018
Product R&D
Natural spots
HotSpot Therapeutics’ small molecules take a page from natural allostery
Items per page:
1 - 10 of 33